Rhythm Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Rhythm Pharmaceuticals, Inc. on June 24, 2026. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
As of the April 27, 2026 record date, there were 68,530,107 shares of common stock and 115,000 shares of Series A convertible preferred stock outstanding. Approximately 92% of eligible votes were present at the meeting. The following proposals were approved:
- Item 1 (Director Election): David W. J. McGirr and David P. Meeker, MD were elected as Class III Directors to serve until the 2029 Annual Meeting.
- Item 2 (Auditor Ratification): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026, was ratified.
- Item 3 (Executive Compensation): The advisory approval of the compensation of named executive officers was passed.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific vote counts for the "Say-on-Pay" proposal (Item 3), which received 50,368,659 votes FOR and 11,467,157 votes AGAINST.
- Confirm the total eligible vote count of 69,675,938, which includes voting rights from Series A convertible preferred stock.
- Review the Definitive Proxy Statement referenced in the filing for detailed biographies of the newly elected directors and the full compensation discussion.